Product Code: 55358
The pharmaceutical contract manufacturing (CMO) market is expected to register a CAGR of over 7.75% during the forecast period 2019 - 2024. With the growing demand for generic medicines and biologics, the capital-intensive nature of the business, and the complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in contracting with a CMO (contract manufacturing outsourcing) for both clinical and commercial stage manufacturing. Additionally, pharmaceutical companies have been directing their priorities toward the core areas of competency, and hence, prefer not to dispense available resources, expertise, and technology on formulating the final dose of medicines.
- In order to adapt to the paradigm shift in the biotechnology industry and the present biopharmaceutical industry trends, CMOs have decided to move away from solely renting manufacturing units to a business model that offers extensive development and production support.
- CMOs and contract development and manufacturing organizations (CDMO) individually or together have started offering many specialized, value-added services for customers with early-stage development needs and for those who require support to generate a biologics license application (BLA) enabling process validation data package.
- CMOs have begun offering early development support to their customers, along with fully integrated services, which include specialized services like aseptic fill-finish. Though the concept of CDMO was introduced earlier, it has been fully realized over the last few years.
- The costs invested in R&D are continuously increasing, and yet the useful results returned from these processes are becoming rarer. Many companies have realized that moving this part of the business overseas and taking advantage of the still-emerging pharmaceutical markets is an effective method of cutting costs.
- Despite the existing evidence regarding cost savings and competences that can be accrued, many companies are reluctant to give up that control, going so far as to state that logistics are a core competency for the company. However, that scenario seems to be changing slowly.
Scope of the Report
A contract manufacturing organization (CMO), called a contract development and manufacturing organization (CDMO), is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing
Key Market Trends
Active Pharmaceutical Ingredient (API) Manufacturing is Expected to Register a Significant Growth
- The demand for API manufacturing has witnessed a sustained rise in the past few years, and it is expected to continue growing steadily, with further patent expiries expected in the future and a subsequent increase in global generic production capacities. Most of the companies in this industry are increasingly focusing on the development of biological APIs, which is driving the API market. The general prescription drug sub-segment occupies a major share in the API manufacturing segment, as compared to OTC drugs.
- Other factors driving the growth of the API segment includes stringent government initiatives in the healthcare sector, innovation in biologics, and rise in the incidence of cancer and age-related diseases. However, strict European regulatory policies may hinder the segment's growth.
- Captive manufacturers are currently leading the API market; however, they are slowly expected to lose their market share to contract manufacturers toward the end of the forecast period. This is due to the complex and expensive in-house manufacturing of API and increasing competition from emerging players in this industry.The increasing emphasis on high-potency APIs is driving the growth of the segment. The novel technologies for HPAPIs can potentially change the in-out balance of CMOs in this fast-growing segment.
- As the big pharma companies continue to scale down on manufacturing, greater opportunities for the CMOs are expected, both in the biopharmaceutical and small molecule API segments.
United States is Expected to Account for a Major Share
- The United States, which in in North America, is the world's largest market for drugs and accounts for almost half of the R&D spending in pharmaceutical and biotechnology markets. Hence, CMOs play a critical role in this market and have invested in new facilities and technologies to cater to a wide range of outsourcers.The United States is expected to face strong competition from Asia-Pacific CMO providers, especially in solid dose formation.
- The consolidation of CMOs is expected to occur within the next five years, as the competitors will either leave the industry, or abandon a specific area within the industry, or go out of business. This improves the pricing power of value-added CMOs.
- Companies, such as Catalent and Patheon, have an established customer base in the United States and are leaders in oral and sterile dose formulations. These companies have been aggressive in expanding their products/services/capabilities through strategic alliances. With the recent acquisition of Confab, DPT Laboratories has become the global leader in prescription semi-solid and liquid formulations, acquiring proprietary products.
The pharmaceutical contract manufacturing market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with a prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability.
The companies operating in the market are also acquiring start-ups working on enterprise network equipment technologies to strengthen their product capabilities.
- In April 2017, Famar announced the closure of the acquisition of a manufacturing site from Bayer, located at Pointe-Claire, Canada, with the transfer of full ownership of the plant to Famar.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
Table of Contents
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Introduction to Market Drivers and Restraints
- 4.3 Market Drivers
- 4.3.1 Increasing Outsourcing Volume By Big Pharmaceutical Companies
- 4.3.2 Expansion In The Service Offering Of CMOS
- 4.3.3 Advent Of CDMO Model Into The Market
- 4.3.4 Increasing Investments In R&D
- 4.4 Market Restraints
- 4.4.1 Increasing Lead Time & Logistics Costs
- 4.4.2 Stringent Regulatory Requirements
- 4.4.3 Capacity Utilisation Issues Affecting The Profitability Of Cmos
- 4.5 Value Chain / Supply Chain Analysis
- 4.6 Industry Attractiveness Porters Five Force Analysis
- 4.6.1 Threat of New Entrants
- 4.6.2 Bargaining Power of Buyers/Consumers
- 4.6.3 Bargaining Power of Suppliers
- 4.6.4 Threat of Substitute Products
- 4.6.5 Intensity of Competitive Rivalry
- 4.7 Technology Snapshot
- 4.7.1 Dosage Formulation Technologies
- 4.7.2 Dosage Forms by Route of Administration
5 MARKET SEGMENTATION
- 5.1 By Type
- 5.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
- 5.1.2 Finished Dosage Formulation (FDF) Development & Manufacturing
- 5.1.3 Secondary Packaging
- 5.2 Geography
- 5.2.1 North America
- 126.96.36.199 US
- 188.8.131.52 Canada
- 5.2.2 Europe
- 184.108.40.206 Germany
- 220.127.116.11 UK
- 18.104.22.168 France
- 22.214.171.124 Italy
- 126.96.36.199 Rest of Europe
- 5.2.3 Asia Pacific
- 188.8.131.52 China
- 184.108.40.206 Japan
- 220.127.116.11 India
- 18.104.22.168 Australia
- 22.214.171.124 Rest of Asia-Pacific
- 5.2.4 Latin America
- 126.96.36.199 Brazil
- 188.8.131.52 Argentina
- 184.108.40.206 Mexico
- 220.127.116.11 Rest of Latin America
- 5.2.5 Middle East and Africa
- 18.104.22.168 UAE
- 22.214.171.124 Saudi Arabia
- 126.96.36.199 South Africa
- 188.8.131.52 Nigeria
- 184.108.40.206 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 Baxter BioPharma solutions
- 6.1.3 Boehringer Ingelheim International GmbH.
- 6.1.4 Jubilant Life Sciences Limited
- 6.1.5 Recipharm AB
- 6.1.6 Catalent Inc.
- 6.1.7 Recipharm AB
- 6.1.8 Patheon Inc
- 6.1.9 Famar S.A.
- 6.1.10 Aenova Group
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS